Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2'-fucosyllactose + Bifidobacterium animalis subsp. lactis BB-12
- Development stage
- Preclinical
- Lead developer
- Chr. Hansen
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
This experimental synbiotic combination consists of the human milk oligosaccharide (HMO) prebiotic **2'-fucosyllactose (2'-FL)** and the probiotic strain ***Bifidobacterium animalis subsp. lactis* BB-12**. It is being investigated as a **live biotherapeutic product (LBP)** for the treatment of **autism spectrum disorder (ASD)**. Administered orally, the combination aims to modulate the gut-brain axis by optimizing gut microbiota structure, specifically increasing the abundance of beneficial bacteria such as *Bifidobacteria* and *Akkermansia*. Preclinical studies in valproic acid-induced mouse models have demonstrated that this synbiotic alleviates social deficits and repetitive behaviors, reduces neuroinflammation and neuronal damage, and improves gut barrier integrity. These therapeutic effects are associated with significantly elevated fecal levels of short-chain fatty acids (SCFAs), which play a crucial role in gut-brain communication.
- Other names
- 2'-FL + BB-122'-fucosyllactose and Bifidobacterium animalis subsp. lactis BB-12 synbiotic
Beyond the preview
Go deeper on 2'-fucosyllactose + Bifidobacterium animalis subsp. lactis BB-12.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 2'-fucosyllactose + Bifidobacterium animalis subsp. lactis BB-12.